Non-viral delivery for gene therapy
A next generation gene therapy delivery approachSeveral clinical trials are now under way to explore the efficacy of gene transfer, a type of gene therapy, as a treatment for Duchenne. This entails using a micro-dystrophin – a shortened form of the dystrophin gene – with the aim of producing a functional dystrophin protein that patients’ bodies can utilise.
Current investigational gene transfer candidates for Duchenne make use of an adeno-associated virus (AAV). An AAV is a virus that is not known to cause disease and that acts as the delivery vehicle to carry the micro-dystrophin to patients’ cells.
As viral based gene therapies continue to demonstrate therapeutic benefit in the clinic, DRF believes it is crucial to also invest in non-viral delivery methods. These technologies may provide strategies to complement current viral gene therapies by potentially increasing cargo size, widening patient eligibility and potentially offering methods to re-administer gene therapies to patients who have already received a viral-based therapy.
DRF has provided funding for Solid Biosciences’ non-viral delivery research programme, which has partnered with experts across three different labs, two working in nanoparticle formation to develop and optimise a nanoparticle-based gene delivery system, and one working in exosome development as a further alternative to current gene delivery mechanisms.
Pre-clinical research
£320,000 contribution
2018-2020
Cambridge, MA, USA
Latest research news
Duchenne Care UK podcast series launched
On World Duchenne Awareness Day 2026, we are pleased to share the launch of the Duchenne Care UK podcast series. The series is based on the Duchenne Care UK Patient and Family Guides and break down information into accessible, short episodes …
Duchenne Care UK orthopaedic guideline recognised by NICE
We are pleased to share that NICE has recognised a third set of guidelines – the orthopaedic care guidelines that were created and published by the Duchenne Care UK programme that we fund …
Landmark day for Duchenne as Givinostat approved for use in England
On a landmark day for the Duchenne muscular dystrophy community, we are delighted to share that the National Institute for Health and Care Excellence (NICE) has recommended the treatment givinostat (brand name Duvyzat) for use on the NHS in England. In final draft...
Our projects
Learn more about what we fund.
Get involved
Find out how you can help us beat Duchenne.